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In the context of universal access to antiretroviral therapy, the surveillance of human immunodeficiency virus
type 1 (HIV-1) genetic diversity and resistance becomes pivotal. In this work our purpose was to describe the genetic
variability; prevalence of drug-resistance mutations; and genotypic resistance profiles in HIV-1 infected individu-
als under antiretroviral treatment, from the Federal District, Brasília, Central Brazil. The entire viral protease and
codons 19 to 234 of the reverse transcriptase gene from 45 HIV-1 isolates were amplified and sequenced for subtyping
and genotyping. By phylogenetic analysis, 96% of the samples clustered with subtype B and the remaining 4% with
HIV-1 subtype F sequences. One major protease inhibitor resistance-associated mutation, I50V, was detected in 38%
of the samples. Minor mutations were also found at the protease gene: L10I/V (7%), K20M (2%), M36I (11%), L63P
(20%), A71T (2%), and V77I (7%). Many mutations associated with reduced susceptibility to nucleoside or non-
nucleoside reverse transcriptase inhibitors were detected: M41L (11%), E44D (4%), D67N (11%), T69D (2%),
K70R (11%), L74V (2%), L100I (4%), K103N (18%), V118I (9%), Y181C (11%), M184V (18%), G190A (4%),
T215Y (4%), and K219E (4%). This study has shown that 84% of the studied population from the Federal District,
showing evidences of therapy failure, presented viral genomic mutations associated with drug resistance. The main
antiretrovirals to which this population showed resistance were the PI amprenavir (38%), the NNRTIs delavirdine,
nevirapine (31%), and efavirenz (24%), and the NRTIs lamivudine (18%), abacavir, and zidovudine (13%).
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Human immunodeficiency virus type 1 (HIV-1) has
been classified into nine group M genetic subtypes: A-D,
F-H, J, and K. Recombination between these subtypes
has led to the generation of many circulating recombinant
forms (CRF). Fifteen different CRFs have already been
identified and may play a major role in local epidemics.
These HIV-1 group M genetic forms account for most of
HIV infections worldwide (Robertson et al. 1999, Thomson
et al. 2002, Rambaut et al. 2004).
HIV-1 genetic forms may have variable biological prop-
erties and display different geographical prevalences, jus-
tifying the need for regional characterization and surveil-
lance. The study of HIV-1 genetic variability in distinct
regions of the world is also important in the design of
more efficient HIV vaccines, which may include the circu-
lating subtypes. Recent data indicate that viral subtypes
may influence immune responses and the effectiveness
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of antiretroviral treatment (Thomson et al. 2002, Perrin et
al. 2003).
To date, therapy options for the management of HIV-1
disease include 6 nucleoside and 1 nucleotide reverse tran-
scriptase inhibitors (NRTI), 3 non-nucleoside reverse tran-
scriptase inhibitors (NNRTI), and 7 PR inhibitors (PI).
However, data have shown the emergence of HIV-1 drug
resistance mutations in treated and untreated individuals
(Hirsch et al. 2003, Shafer 2003).
The Brazilian Ministry of Health has been sponsoring
free access to HIV treatment for AIDS patients since 1996
(Dumans et al. 2002, Tanuri et al. 2002). Nevertheless, the
selection of viral resistant strains is a major problem for
the medical management of infected individuals and ac-
counts for the transmission of these variants to non-in-
fected people. This represents an important public health
problem, particularly in areas where antiretroviral drugs
have been widely used for many years (Little et al. 2002,
Hirsch et al. 2003).
A previous study has shown a low frequency of wild
type isolates among treated patients from the Federal Dis-
trict in comparison with those from other Brazilian sites
(Tanuri et al. 2002). Moreover, in a previous report we
have found a high prevalence (84.2%) of virus strains
from Federal District samples collected at 1998 containing
resistance mutations (Cerqueira et al. 2004). Here, we de-
scribe the genetic diversity of HIV-1 PR and RT sequences,
as well as the genotypic resistance profiles of HIV-1 iso-
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lates from infected individuals under antiretroviral treat-
ment, living in the Federal District, Central Brazil during
the year of 2002 in order to monitor the prevalence of drug
resistance mutations and genetic subtypes.
MATERIALS AND METHODS
Study population - The starting material was RNA
previously extracted for viral load measurement. These
HIV-1 RNA samples from 45 infected individuals were col-
lected at a Public Health Laboratory located at the Federal
District (Lacen-DF), in 2002. All samples belonged to in-
dividuals who had viral load counts higher than 100,000
copies/ml and were under antiretroviral drug treatment.
The viral load data were collected and patient identifying
information was excluded from sample tubes. The Com-
mittee on Human Research Ethics granted prior approval
to this research project.
RNA extraction and cDNA synthesis - Viral RNA was
extracted from plasma samples using the Nucleon-HT Kit
(Organon-Teknika) according to the manufacture’s pro-
tocol, and stored at –70°C. Complementary DNA (cDNA)
was synthesized from 5 µl of extracted RNA using 2 U of
M-MuLV RT (Gibco) plus 0.2 mM dNTP, 2 U RNAse in-
hibitor (Pharmacia Biotech), and 0.5 µg of random primer.
The reaction condition was 37°C for 60 min.
RT and PR gene amplification and sequencing - Two
different HIV-1 genomic regions were targeted for poly-
merase chain reaction (PCR) amplification: PR and RT. The
cDNA was used as template in a two-stage nested PCR
amplification of the full-length PR gene and of a fragment
corresponding to codons 19 to 234 of the RT gene, which
harbors most of the known resistance mutations to li-
censed antiretroviral drugs. PR gene amplification used
the outer primers DP10/DP11 (20 nM) (Gibco) and the in-
ner primers DP16/DP17 (20 nM) (Gibco) (Brasil 1999). To
amplify the fragment of the RT gene, we used the outer
primers RT09/RT12 (20 nM) (Gibco) and the inner primers
RT01/RT04 (20 nM) (Gibco) (Brasil 1999). PCR was carried
out in 10 mM Tris-HCL (pH 8.3) (Life Technologies, Gibco),
50 mM KCl (Sigma Chemicae Co.), 1.5 mM MgCl2 (Life
Technologies, Gibco), 0.2 mM each dNTP (Gibco), 0.8 µM
each primer, 2 U Taq polymerase (Gibco), and 5 µl cDNA
solution. An aliquot (1 µl) of the primary PCR product was
used for nested PCR in the same conditions. The PR am-
plification gave a 297-bp product and, the RT amplifica-
tion, a 647-bp product.
The PCR products were subjected to direct popula-
tion sequencing of both strands, using the inner PCR
primer set. Nucleotide sequences were determined auto-
matically by the dideoxy chain termination method, in a
Megabace System (Amersham-Pharmacia). Sequence edi-
tion and alignments were performed using the CLUSTAL
W multiple-sequence alignment program (Thompson et
al. 1994). Minor manual adjustments were made to improve
the alignments.
Genotyping - The aligned DNA sequences were trans-
lated into amino acids and mutations were defined as dif-
ferences from the HIV-1 consensus subtype B sequence
(available at: http://www.hiv.lanl.gov/content/hiv-db/
CONSENSUS). Information on mutations associated with
resistance was obtained from the International AIDS So-
ciety-USA (IASUSA) guidelines (Johnson et al. 2003).
Interpretation of genotypic data was performed by HIVdb
program at the HIV RT and PR Sequence Database (http:/
/hivdb.stanford.edu) (Rhee et al. 2003). This is a comput-
erized rules-based algorithm that provides the similarity
of user-submitted sequences with the closest subtype
reference sequence and classifies the virus as “suscep-
tible”, “possible resistant”, or “resistant” to each anti-
retroviral agent. In the PR gene, resistance mutations were
classified as major or minor, according to recommenda-
tions of IASUSA (Johnson et al. 2003).
Phylogenetic analysis - For each HIV-1 isolate, PR
and RT sequences were grouped. The resulting sequences
were aligned with reference sequences of various sub-
types from the Los Alamos HIV database (http://hiv-
web.lanl.gov), using CLUSTAL W program. Phylogenetic
analysis was performed by the neighbor-joining distance
method with Kimura’s two-parameter correction (Kimura
1980), by using PHYLIP package (Felsenstein 1993). The
SIVCPZ PR and RT sequences were also grouped and
used as outgroup for phylogenetic comparisons. Tree was
drawn using TREE-VIEW program and the reliability of
the branching orders was estimated by the bootstrap ap-
proach (1000 replicates).
Sequences that did not branched with the reference
subtypes were analyzed by SimPlot version 2.5 program
(Ray 1999).
RESULTS
All 45 samples were successfully amplified in PR and
RT regions. Based on pol PR and RT sequence, most of
our isolates (n = 43.96%) clustered phylogenetically with
subtype B reference sequences. The sequences of iso-
lates DF02.14 and DF02.40 (4%) formed a separate branch
(Fig. 1) and were analyzed by SimPlot program, which
suggested the occurrence of PR B/RT F recombinants (data
not shown).
The distribution of HIV-1 resistance-associated muta-
tions in the PR and RT genes is shown in Fig. 2. At PR
sequences, only one major mutation, I50V, was detected
in 17 sequences (38%). Minor mutations were seen at
positions L10I/V (7%), K20M (2%), M36I (11%), L63P
(20%), A71T (2%), and V77I (7%), but occurred at low
frequencies, with the exception of those at positions 36
and 63 (Fig. 2A).
The distribution of known resistance mutations in RT
sequences was as follows: M41L (11%), E44D (4%), D67N
(11%), T69D (2%), K70R (11%), L74V (2%), V118I (9%),
M184V (18%), T215Y (4%), and K219E (4%), which are
associated to NRTI resistance, and L100I (4%), K103N
(18%), Y181C (11%), and G190A (4%), which are associ-
ated to NNRTI resistance (Fig. 2B).
In addition to the resistance-associated mutations
found within the PR and RT regions, many other polymor-
phisms were detected (data not shown). These amino acid
variants at polymorphic positions do not cause drug re-
sistance by themselves and emerge as genetics variants
with apparently equivalent replication capacity (Holguín
et al. 2002). At the PR gene, the most frequent polymor-
phism occurred at codon N37 (67%) and, at the RT gene,
58% of the genotypes showed polymorphism at codon
I135.
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In total, 84% of HIV-1 infected subjects from the Fed-
eral District presented viral genomic mutations associ-
ated with drug resistance. Mutations associated with PI
resistance were found at 73% of the viral sequences and
those associated with RTI resistance at 42%. Among these
sequences containing RTI resistance-associated muta-
tions, 36% was associated with NRTI resistance and 31%
with NNRTI resistance.
The inferred levels of resistance were deduced from
the amino acid sequences. To each sample, the PR and RT
regions were classified in one of the following levels of
drug resistance: susceptible, intermediate resistance or
resistant. Of the 45 samples, 62% showed resistance to at
least one of the antiretrovirals analyzed. Sixteen patients
Fig. 1: neighbor-joining protease and reverse transcriptase tree including all specimens sequenced (DF02.n) and indicating the putative
subtype of each isolate. Reference sequences for A, B, C, D, and F clades from the Los Alamos database were also included. The Kimura two-
parameter method of estimating genetic distances was used. Numbers next to the nodes of the tree represent bootstrap values (1000
replicates).
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(36%) carried viruses predicted to be susceptible to all PI,
NRTI, and NNRTI. No patients had viruses classified as
resistant to all of these drugs. Viruses that were predicted
to be sensitive to all PI were found in 62%, to all NRTI in
64%, and to all NNRTI in 69% of the individuals studied
here (Fig. 3).
The highest level of resistance was observed to
amprenavir (APV) (38%), the only PI to which resistant
samples were detected. Viruses classified as resistant to
all NNRTI were found in 24% of the samples, whereas
those resistant only to delavirdine (DLV) and nevirapine
(NVP) were detected at a higher frequency (31%). For
NRTIs, the frequencies of resistant isolates varied from
18% (lamivudine - 3TC) to 2% (tenofovir - TDF) (Fig. 3).
The high percentages of samples resistant to NNRTI ob-
served on Fig. 3 were not previously described at the
Federal District, as samples from 1998 were classified as
susceptible to all drugs of this class (Cerqueira et al. 1994).
DISCUSSION
Several recent reports have shown that the numerous
selection pressures on the pol gene make it suitable for
phylogenetic studies (Njouom et al. 2003). HIV-1 subtypes
were determined here by sequencing the PR and RT genes
of plasma viruses, an approach that has proved to be
useful by other investigators (Ramos et al. 1999, Holguín
et al. 2002).  PR and RT sequences were grouped because
phylogenetic analysis of PR sequences appears to be less
trustworthy than that of RT. This is probably due to the
size of the PR gene, which has fewer variations among
Fig. 2: percentages of protease sequences with protease inhibitors (PI)-associated major and minor mutations (A) and of reverse tran-
scriptase (RT) sequences with nucleoside RT (NRTI) and non-nucleoside RT (NNRTI) inhibitor-associated resistance mutations (B).
A B
Fig. 3: frequencies of resistance levels to non-nucleoside (NNRTI) and nucleoside (NRTI) reverse transcriptase inhibtors and to protease
inhibitors. The horizontal bars indicates the frequencies of susceptible, intermediate resistance, and resistant samples to NNRTIs and NRTI
reverse transcriptase inhibitors and to PI.
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subtypes and less phylogenetically informative sites.
Moreover, the analysis of the PR sequences alone may be
doubtful due to closely-related subtypes or recombinant
viruses (Gonzales et al. 2001, Pasquier et al. 2001).
Brazil is a huge country and differences in the pattern
of HIV-1 subtypes distribution have been identified among
the geographic regions. Thus it is important to monitor
subtype profiles, as their distribution has local determi-
nants, and data from one site cannot be generalized for
the entire country or even for a single geographic region.
HIV-1 subtype B is the most prevalent in our country,
followed by subtype F1, with sporadic cases of subtypes
C, D, and A (Rossini et al. 2001, Morgado et al. 2002, Tanuri
et al. 2002, Gadelha et al. 2003, Soares et al. 2003).
We performed the HIV-1 genetic subtyping on 45
samples from the Federal District, based on phylogenetic
analysis of the PR and RT genes. Our results reflect sub-
types distribution previously observed in other Brazilian
regions, as subtype B was the most prevalent (96%). The
remaining two samples (4%) seem to be recombinants
between subtypes B and F, what has also been described
in Brazil and may explain why they do not branch with the
reference samples in the phylogenetic tree (Ramos et al.
1999, Gadelha et al. 2003, Cerqueira et al. 2004). Studies
are being conducted in order to analyze subtype homolo-
gies of these samples based on additional genes.
Eighty four percent of the HIV-1 infected studied sub-
jects from the Federal District, who were under anti-
retroviral treatment and with viral load counts higher than
100,000 copies/ml, presented viral genomic mutations as-
sociated with drug resistance. This result is close to that
reported in another Brazilian study, where 84.7% of the
virus strains showed resistance-associated mutations
(Tanuri et al. 2002) and to the frequency of 84.2% that we
have found on samples collected at 1998 (Cerqueira et al.
2004).
The higher prevalence of resistance mutations in the
PR region, when compared to RT, could be associated
with extensive use of PI for the treatment of infected indi-
viduals in the Federal District. This may be particularly
true for APV, as this PI-associated major mutation, I50V,
was found in 38% of the subjects analyzed. Alternatively,
I50V may represent a signature of HIV-1 strains from the
Federal District. This calls for further investigation, al-
ready in course.
PR minor mutations were observed at low frequencies
(2 to 11%), with the exception of L63P, which was de-
tected at 20% of PR sequences. Position 63 is the most
polymorphic codon of the PR, which may explain this re-
sult (Rhee et al. 2003). The detection of PR minor muta-
tions at 36% of the samples is of concern since these
mutations can reduce the genetic barrier and yield a faster
selection of resistant strains when compared to wild type
isolates (Brindeiro et al. 2003).
At the RT gene, K103N was the most frequent (18%)
NNRTI-associated mutation, which agrees with data re-
porting that this mutation occurs more commonly than
any other mutation in patients receiving NNRTI and may
cause resistance to each one of them (Shafer 2002). Amino
acid substitutions at codon 135 were detected at a high
frequency (58%). This position comprises one of the three
mutations that have recently been identified as novel sites
that may influence susceptibility to NNRTI (Magiorkinis
et al. 2002, Shafer 2003).
Sixty-two percent of patients under antiretroviral
therapy and with high viral load counts (> 100,000 copies/
ml) showed resistance to at least one of the antiretrovirals
analyzed. This result is probably related to antiretroviral
drug treatment selective pressure and suggests that these
patients were not responding to antiretroviral therapy,
underling the necessity of their monitoring with regard to
the possibility of changing current regimens. For 1998
samples, a similar rate (58%) of resistance to at least one
antiretroviral was observed (Cerqueira et al. 2004).
Only 36% of the sequences were classified as suscep-
tible to all antiretroviral drugs. Of great importance was
the high level of resistance to the PI amprenavir (38%),
and to the NNRTI delavirdine and nevirapine (31%). This
might result from the fact that a single mutation may cause
high-level resistance to NNRTI(s) and may also reflect
the high level of cross resistance among these drugs, as
well as their wide use in the Federal District (Shafer 2002).
It is interesting to note that mutations associated to
NNRTI resistance were not previously found in the Fed-
eral District (Cerqueira et al. 2004). However, 24% of the
samples analyzed here were classified as resistant to all
NNRTI and, among RT inhibitors, the highest levels of
resistance were observed to the non-nucleoside ones (Fig.
3). These results suggest the selection of NNRTI resis-
tant strains due to the pressure of these drugs after their
introduction in the Federal District. We might also specu-
late that a significant increase on resistance is expected
as these drugs become more used on antiretroviral treat-
ments.
The knowledge of resistance profiles of virus strains
from each locality may be helpful to guide the treatment
of HIV infected individuals, reducing effective public
health costs. It is particularly important for São Paulo and
Brasília, where antiretroviral drugs were first made avail-
able and probably the patients of these sites are exposed
to anti-HIV therapy longer than people from other sites.
Drug pressure could have driven the selection of resis-
tant strains and may put at risk the efforts in controlling
AIDS morbidity and mortality by antiretroviral therapy.
Moreover, these drug resistant strains can be transmitted
to non-infected individuals, contributing to a spread of
resistance among the Brazilian population (Brenner et al.
2000, Little et al. 2002, Tanuri et al. 2002, Hirsch et al. 2003).
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